Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates in the allergy, respiratory, and opioid overdose markets include: SYMJEPI (epinephrine) Injection 0.3mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis; ZIMHI (naloxone HCL Injection, USP) five mg/0.5 mL for the treatment of opioid overdose; and Tempol, an investigational drug. Co. also has a microbicide product candidate, named C31G.
|
Free ADMP Email Alerts: Get SEC Filing Alerts Get Dividend Alerts |
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |